The Experts below are selected from a list of 3018 Experts worldwide ranked by ideXlab platform
Giuseppe Del Priore - One of the best experts on this subject based on the ideXlab platform.
-
Radiomic texture analysis correlates with PDAC patient outcomes on SM-88.
Journal of Clinical Oncology, 2020Co-Authors: Allyson J. Ocean, Ronald L. Korn, Semmie Kim, Andre Burkett, Ziad Hindosh, Zak Nolte, Giuseppe Del PrioreAbstract:e16776Background: SM-88 (racemeTyrosine) is a dysfunctional Tyrosine Derivative; previous studies demonstrated a well-tolerated profile with encouraging efficacy. Recent advances in image analysis ...
-
SM-88 therapy in patients with advanced or metastatic pancreatic cancer.
Journal of Clinical Oncology, 2018Co-Authors: Steve Hoffman, Giuseppe Del Priore, Jeanetta Stega, Patricia Zawisny, Zachary Gostout, Maria Loushin, Ben R TaylorAbstract:457Background: SM-88 (Tyrosine Derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg Effect in combination ...
Robert M. Williams - One of the best experts on this subject based on the ideXlab platform.
-
synthetic studies toward mpc1001 preparation of a β hydroxyl Tyrosine Derivative
Tetrahedron Letters, 2012Co-Authors: Paul T Schuber, Robert M. WilliamsAbstract:A procedure for the asymmetric synthesis of a novel β-hydroxy-α-amino acid Derivative to be used in the preparation of the natural product MPC1001 and analogs has been developed. The amino acid was efficiently prepared in six steps via a Mukaiyama aldol reaction via a diphenyloxazinone and 3-bromo-4-methoxybenzaldehyde.
-
Synthetic studies on ecteinascidin 743: asymmetric synthesis of the versatile amino acid component
Tetrahedron Letters, 2003Co-Authors: Wei Jin, Robert M. WilliamsAbstract:The asymmetric synthesis of the modified Tyrosine Derivative as a basic building block for the ecteinascidin and safracin family of antitumor alkaloids has been achieved in nine steps and 39% overall yield.
-
Entry into the bi-aryl moiety of the TMC-95 proteasome inhibitors via the Stille protocol
Tetrahedron Letters, 2001Co-Authors: Brian K. Albrecht, Robert M. WilliamsAbstract:Abstract The synthesis of the bi-aryl moiety of the TMC-95 natural products has been achieved via a palladium-catalyzed Stille cross-coupling reaction of an aryl stannane Tyrosine Derivative and 7-iodoisatin.
Steven L Cobb - One of the best experts on this subject based on the ideXlab platform.
-
a direct route for the preparation of fmoc otbu protected iodoTyrosine
Tetrahedron Letters, 2018Co-Authors: Andrew Steer, Hannah L Bolt, William D. G. Brittain, Steven L CobbAbstract:Abstract Herein the synthesis of an Fmoc/O t Bu orthogonally protected iodoTyrosine Derivative is reported. This has been achieved via a simple two-step process in an overall 58% yield from commercially available Fmoc-Tyr( t Bu)-OH. The Fmoc/O t Bu orthogonally protected iodoTyrosine was also shown to be amenable to Suzuki-Miyaura cross-coupling to deliver a novel bi-aryl Tyrosine Derivative.
-
A direct route for the preparation of Fmoc/OtBu protected iodoTyrosine.
Tetrahedron Letters, 2018Co-Authors: Andrew Steer, Hannah L Bolt, William D. G. Brittain, Steven L CobbAbstract:Abstract Herein the synthesis of an Fmoc/O t Bu orthogonally protected iodoTyrosine Derivative is reported. This has been achieved via a simple two-step process in an overall 58% yield from commercially available Fmoc-Tyr( t Bu)-OH. The Fmoc/O t Bu orthogonally protected iodoTyrosine was also shown to be amenable to Suzuki-Miyaura cross-coupling to deliver a novel bi-aryl Tyrosine Derivative.
Ben R Taylor - One of the best experts on this subject based on the ideXlab platform.
-
SM-88 therapy in patients with advanced or metastatic pancreatic cancer.
Journal of Clinical Oncology, 2018Co-Authors: Steve Hoffman, Giuseppe Del Priore, Jeanetta Stega, Patricia Zawisny, Zachary Gostout, Maria Loushin, Ben R TaylorAbstract:457Background: SM-88 (Tyrosine Derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg Effect in combination ...
Andrew Steer - One of the best experts on this subject based on the ideXlab platform.
-
a direct route for the preparation of fmoc otbu protected iodoTyrosine
Tetrahedron Letters, 2018Co-Authors: Andrew Steer, Hannah L Bolt, William D. G. Brittain, Steven L CobbAbstract:Abstract Herein the synthesis of an Fmoc/O t Bu orthogonally protected iodoTyrosine Derivative is reported. This has been achieved via a simple two-step process in an overall 58% yield from commercially available Fmoc-Tyr( t Bu)-OH. The Fmoc/O t Bu orthogonally protected iodoTyrosine was also shown to be amenable to Suzuki-Miyaura cross-coupling to deliver a novel bi-aryl Tyrosine Derivative.
-
A direct route for the preparation of Fmoc/OtBu protected iodoTyrosine.
Tetrahedron Letters, 2018Co-Authors: Andrew Steer, Hannah L Bolt, William D. G. Brittain, Steven L CobbAbstract:Abstract Herein the synthesis of an Fmoc/O t Bu orthogonally protected iodoTyrosine Derivative is reported. This has been achieved via a simple two-step process in an overall 58% yield from commercially available Fmoc-Tyr( t Bu)-OH. The Fmoc/O t Bu orthogonally protected iodoTyrosine was also shown to be amenable to Suzuki-Miyaura cross-coupling to deliver a novel bi-aryl Tyrosine Derivative.
